Halloysite Nanotubes, a Multifunctional Nanovehicle for Anticancer Drug Delivery

Abstract

Targeted drug delivery systems have attracted a great deal of interest by virtue of their potential use in chemotherapy. In this study, multicomponent halloysite nanotubes (HNTs) have been evaluated as a platform to assist and direct the delivery of anticancer drug doxorubicin (DOX) into cancer cells. Folic acid (FA) and magnetite nanoparticles were successfully grafted onto HNTs via amide reaction whereas the drug has been introduced by capitalizing electrostatic interaction between cationic drug and anionic exterior of HNTs, which eventually leads to pH responsive release. The resultant DOX loaded FA-Fe 3 O 4 @HNTs were well characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR) and XRD. The clinical efficacy of the system was validated by confocal microscopy and cell cytotoxicity assay (MTT assay). MTT assay results revealed a high biocompatibility up to a concentration of 200 μg/mL of HNTs, while, DOX loaded FA-Fe 3 O 4 @HNTs were markedly cytotoxic to HeLa cells. This multifunctional nanovehicle has a great potential for cancer diagnosis and therapy, and could further advance the clinical use of nanomedicine.

Gamma-aminobutyric acid loaded halloysite nanotubes and in vitro-in vivo evaluation for brain delivery

“…The negative external surface was attributed to varying external and internal composition (SiO 2 and Al 2 O 3 , correspondingly) (Levis and Deasy, 2002;Guo et al, 2012). Zeta potential results shown in Table 2 demonstrated that zeta potential of nanotubes containing GABA were in the range of -25 mV and -32 mV.…”

“…Time-dependent release profiles of GABA from different nanotube formulations presented in Figure 5 demonstrated sustained release in PBS (pH 7.4) (Guo et al, 2012). Prolonged release of GABA was ascribed to the release of lumen loaded GABA of which the diffusion was substantially retarded by the onedimensional nanotube structure of HNT (Tan et al, 2014).…”

“…GABA release from all nanotube formulations was much lower than its pure form (Abdullayev et al, 2009;Guo et al, 2012). While release from HNT-GABA H1 and HNT-GABA H2 was approximately 50 % within 6 hours, a higher release was determined for HNT-GABA H3 with 70 % release within the same time period.…”

Utilização de argilas fibrosas e tubulares para a liberação modificadas de fármacos: uma revisão

“…HNTs Anti-câncer [23] Ibuprofeno [24] Resveratrol [25] Tetraciclina [26] Benzitriazol [27] Dexametasona [28] Mesalazina [29] Dexametasona, Furosemida e Nefedipina [30] Dialtizem [31] Haloisita modificada com 3-aminopropiltrietoxissilano Ibuprofeno [32] Adesivo modificado de HNTs para uso odontológico Doxiciclina [33] HNTs modificado com sal de triazol Curcumina [34] Compósito de HNTs e materiais biocompatíveis (hialuronato de sódio com polimetacrilato de hidroxietil) para formação de hidrogel 5-fluoracila (5-FU) [35] HNTs modificado com antisurvivina tRNA Fármacos de atividade antitumoral [36] HNTs em microesferas porosas Dopamina; Lacase [37] HNTs modificado com 3-aminopropiltrietoxsilano Aspirina [38] HNTs modificado com ciclodextrinas (unidas aos nanotubos) Curcumina [34] HNTs com ativação básica da estrutura Ofloxacino [39] Compósito de HNTs e poli-ácido lático-co-glicólico (PLGA) Tetraciclina [40,41,42] Nanocompósitos HNTs, grânulos de alginato de sódio e hidroxiapatita para formação de hidrogel Diclofenaco de sódio [43] Microesferas de quitosana, Fe 3 O 4 e HNTs Ofloxacino [44] DNA-envolto em HNTs Doxirrubicina [45] HNTs enxertado com ácido fólico e magnetita Doxirrubicina [46] Compósito de HNTs com polimetilmetacrilato (PMMA) formando cimento ósseo para a substituição de quadril e joelho Sulfato de gentamicina [47] Compósito de HNTs com álcool polivinílico, montmorilonita, metacrilato de polimetila formando filmes Tetraciclina [48] Pellets com HNTs e celulose microcristalina Fentanil [49] Fonte: Arquivos do autor, 2015.…”

In-vitro assessment of cytotoxicity of halloysite nanotubes against HepG2, HCT116 and human peripheral blood lymphocytes

“…A very recent in-vivo toxicity study in a soil nematode Caenorhabditis elegans has also demonstrated high safety prospects of this novel clay even at high concentration of 1000 g/mL [17]. Various studies have shown drug delivery and biological potential of this nanotubular material through in-vitro experiments, yet none has examine cytotoxicity from the perspective of oral drug delivery systems [8,13,[18][19][20].…”